Collegium Pharmaceutical, Inc.

    Jurisdiction
    United States
    LEI
    54930049FXZMTLW8D496
    ISIN
    US19459J1043 (COLL)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €90.35 229.7% undervalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Read full profile

    Fundamentals

    Net revenue
    €603.04M
    Gross margin
    56.7%
    EBIT
    €110.66M
    EBIT margin
    18.4%
    Net income
    €30.94M
    Net margin
    5.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €661.97M +9.8% €250.65M +710.2%
    €607.84M -8.2% €210.54M -16.0%
    €565.36M -7.0% €149.65M -28.9%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Smith Thomas B EVP and Chief Medical Officer -17K $38.42 -$671.50K
    Dreyer Scott EVP & Chief Commercial Officer -16K $38.21 -$626.22K
    SANTINI GINO N/A -5.4K $37.19 -$201.01K
    Dreyer Scott EVP & Chief Commercial Officer -4.9K $38.03 -$184.86K
    Freund John Gordon N/A -12K $34.36 -$400.60K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.6M $48.24M -46K Sell

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications